Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy

Initial applications to focus on the treatment of solid tumor malignancies Clinical trials expected to begin in 2019 PHILADELPHIA, June 27, 2018 -- (Healthcare Sales & Marketing Network) -- Carisma Therapeutics Inc., formerly CARMA Therapeutics, a p... Biopharmaceuticals, Venture Capital Carisma Therapeutics, macrophage, immunotherapeutics, immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news